




The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Enanta Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 418%, being 161% points above the market average of 256%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	436,837	Assets	486,132
Cost of Goods Sold	0	Liabilities	30,552
Intangible Assets	0	Expenses	165,261
Liabilities, Current	24,157	Revenues	122,473
Liabilities, Non-Current	4,916	Stockholders Equity	455,580
Other Assets	40,699	Net Income	-36,168
Other Compr. Net Income	698	Comprehensive Net Income	-35,819
Other Expenses	1,149	BaseVar	405,868
Other Liabilities	1,479	ECR before LimitedLiability	371%
Other Net Income	6,620	Economic Capital Ratio	418%
Other Revenues	122,473		
Property and Equipment	8,596		
Research and Development	136,756		
Selling, General and Administrative Expense	27,356		